Since @Yenom23 tagged those new posters I thought to supply them...

Since @Yenom23 tagged those new posters I thought to supply them with some factual information. Like I said, $10 per month isn't even expense here, you spend that much on a coffee and somehow no-one is concern about the massive discrepancy in the device and subscription sales????

It isn't just the very low uptake in 2021 with only 15 devices sold but of the 1.2K device sold the previous year 2020 at most only 10 of them decided to fully subscribed for the year and this is for a device which you guys have been ramped monitoring of wheeze is very important for Astham management when I told you guys wheeze doesn't mean you are having an Asthma attack or even Asthma.

And who cares if this is a different sales model in a different market, the patient still need to find wheezo useful for RSH to receive the monthly subscription fee and LOL at @Yenom23 suggesting RSH will get $1K USD per month for each wheezo user signed under CPT, I can know understand why RSH did an unsuccessful T/O of ADR which only have a MC of $24M. I thought it was very strange at that time when everyone else was ramping this announcement.